Dashboard

REGENXBIO, Inc. (RGNX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

CEO

Kenneth T. Mills

Employees

257

Industry

Neurology Biopharmaceuticals

Sector

Healthcare

Headquarters

Rockville

Exchange

NASDAQ

Summary Stats

Market Cap

870M

Revenue

474M

Net Income

101M

EPS

$2.29

Price-to-Earnings

8.81

Price-to-Book

1.26

Debt-to-Equity

0.49

News

Analyst Ratings

Price targets projected by 8 analysts

High

$100.00

Average

$57.50

Low

$31.00

Ratings calculated by 8 analysts

Buy

6

Hold

2

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Missed by -$0.26

Actual

-$1.58 -19.7%

Consensus

-1.32

Report Date

Year Ago

-1.2

Year Ago Change %

Down 31%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites